Process development services for cell and gene therapy

OXB offers end-to-end viral vector process development services for cell and gene therapy programs, including serum-free suspension process development, parameter optimization, and integrated lab-to-launch support. Our solutions ensure high-yield, reproducible, and scalable processes ready for clinical and commercial applications.

Over the years, OXB has consistently refined its processes to drive higher yields and improved product quality. Our scientists have explored the design space extensively, identifying and optimizing the critical levers that govern productivity and consistency. By focusing on these parameters, OXB delivers viral vector processes that are not only robust and reproducible but also scalable for both clinical and commercial applications.

Yes. Unlike many CDMOs, OXB provides expertise in construct design and optimization to ensure viral vectors are engineered for productivity, potency, and manufacturability. By addressing construct considerations at the earliest stage, we help reduce downstream risks and accelerate successful process development.

OXB takes an integrated approach to upstream and downstream development. On the upstream side, we optimize cell culture, media, and bioreactor conditions to achieve consistent high yields. Downstream, we innovate in purification and recovery methods to maximize yield and ensure efficiency, scalability, and quality that meets regulatory expectations.

OXB is among the few CDMOs offering dedicated formulation development for viral vectors. Our scientists design and develop formulations for various vectors with considerations to route of delivery that enhance stability, extend shelf life, and preserve potency throughout clinical and commercial supply chains. This capability ensures therapies maintain quality from production to patient administration.

Using our dedicated platforms, LentiVector™ platform for lentivirus and inAAVate™ platform for AAV, OXB delivers tailored process development, streamlined workflows, and regulatory-ready designs. This platform approach accelerates timelines, minimizes risk, and enables scalable, high-quality viral vector production for multiple applications.

OXB’s streamlined process development workflows and platform-based strategies reduce development timelines by enabling rapid optimization, early scalability, and smooth tech transfer to GMP manufacturing. This helps programs move faster from research to clinical readiness with lower risk and cost.

All process development activities are performed with regulatory considerations in mind, including quality-by-design principles, robust analytics, and process documentation. This ensures smooth tech transfer to GMP manufacturing and supports eventual IND, CTA, or commercial submissions.

OXB combines scientific expertise, platform technologies, and multi-vector experience to deliver reproducible, high-yield, and scalable viral vector processes. Our solutions minimize development risk, accelerate timelines, and ensure a smooth transition to GMP manufacturing, helping you bring therapies to clinic faster.